Does USTEKINUMAB Cause Interstitial lung disease? 112 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 112 reports of Interstitial lung disease have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.1% of all adverse event reports for USTEKINUMAB.
112
Reports of Interstitial lung disease with USTEKINUMAB
0.1%
of all USTEKINUMAB reports
13
Deaths
31
Hospitalizations
How Dangerous Is Interstitial lung disease From USTEKINUMAB?
Of the 112 reports, 13 (11.6%) resulted in death, 31 (27.7%) required hospitalization, and 8 (7.1%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 112 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which USTEKINUMAB Alternatives Have Lower Interstitial lung disease Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE